JPH0799936A - Albumen having decreased allergen content - Google Patents

Albumen having decreased allergen content

Info

Publication number
JPH0799936A
JPH0799936A JP5269679A JP26967993A JPH0799936A JP H0799936 A JPH0799936 A JP H0799936A JP 5269679 A JP5269679 A JP 5269679A JP 26967993 A JP26967993 A JP 26967993A JP H0799936 A JPH0799936 A JP H0799936A
Authority
JP
Japan
Prior art keywords
egg white
glucosidase
albumen
present
allergen content
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5269679A
Other languages
Japanese (ja)
Inventor
Toshihiro Ito
俊宏 伊藤
Noboru Sakaguchi
騰 坂口
Akifusa Kawai
昭房 川合
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiyo Kagaku KK
Original Assignee
Taiyo Kagaku KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiyo Kagaku KK filed Critical Taiyo Kagaku KK
Priority to JP5269679A priority Critical patent/JPH0799936A/en
Publication of JPH0799936A publication Critical patent/JPH0799936A/en
Pending legal-status Critical Current

Links

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Meat, Egg Or Seafood Products (AREA)

Abstract

PURPOSE:To obtain an albumen having decreased allergen content, keeping the thermal coagulation property and frothing property and suitable as a food for a patient with albumen allergy by treating albumen with a glucosidase. CONSTITUTION:This albumen having decreased allergen content can be prepared by treating albumen with a glucosidase such as endo-beta-N-acetylglucosaminidase e.g. at 25-70 deg.C.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、グルコシダーゼを作用
させることにより得られることを特徴とする低アレルゲ
ン化卵白に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a hypoallergenized egg white which is obtained by allowing glucosidase to act.

【0002】[0002]

【従来の技術】アレルギーは紀元前から知られている疾
病であるが、近年、日常よく耳にする疾病となり、この
20〜30年の間、成人病や癌に匹敵するにまで増加
し、また難治化し問題となってきている。その中で特
に、生まれたばかりの乳幼児から成人にいたるまで、食
品由来のアレルギー疾患が増加傾向にある。
2. Description of the Related Art Allergy is a disease that has been known since BC, but in recent years, it has become a commonly heard disease, and during the last 20 to 30 years, it has increased to a level comparable to adult diseases and cancer, and is also intractable. Has become a problem. Among them, food-derived allergic diseases tend to increase, especially from newborn infants to adults.

【0003】個体が外界の進入物に対して、自己と同一
(同質)か、異物(異質・非自己)であるかを識別する
能力を免疫反応と呼び、この中には個体を防御する有利
な反応(予防接種・感染による抗体獲得)と、個体に不
利な過敏反応とがあり、アレルギーは後者に属してい
る。
[0003] The ability of an individual to discriminate against an intruder from the outside world, which is the same (homogeneous) as itself or a foreign substance (heterogeneous / non-self), is called an immune reaction. There are various reactions (antibody acquisition by vaccination / infection) and hypersensitivity reaction which is disadvantageous to individuals, and allergy belongs to the latter.

【0004】アレルギー反応はその発症のメカニズム等
からI〜IV型に分類される。I型アレルギー反応は即
時型反応とも呼ばれ、アレルゲンに接して、数秒から数
時間内に起こるものであり、食物アレルギーの大部分は
この型に属している。このI型アレルギー反応の症状と
しては、気管支喘息、アトピー性皮膚炎等があり、時に
は、血圧低下、意識消失、心停止等、急激に重篤な反応
を起こすことがある。
Allergic reactions are classified into types I to IV according to the mechanism of their onset. The type I allergic reaction, which is also called an immediate type reaction, occurs within a few seconds to a few hours upon contact with the allergen, and most food allergies belong to this type. Symptoms of this type I allergic reaction include bronchial asthma, atopic dermatitis, and the like, and sometimes a sudden and serious reaction such as a decrease in blood pressure, loss of consciousness, and cardiac arrest may occur.

【0005】食物アレルゲンのうち卵、牛乳、大豆は三
大アレルゲンと言われ、小児にとって特に問題となって
いる。食物アレルギーの治療は、通常、アレルゲンとな
る食物を日常の食品から取り除くことにより行なわれ
る。この場合、乳幼児にとって成長に必要な良質の蛋白
質食品を摂取できなくなるため、十分な栄養が得られず
体の成長を阻害することにもなりかねない。
Of the food allergens, egg, milk and soybean are said to be the three major allergens, which are especially problematic for children. Treatment of food allergies is usually carried out by removing foods that are allergens from daily foods. In this case, since infants cannot ingest high-quality protein foods necessary for growth, sufficient nutrition cannot be obtained, which may hinder the growth of the body.

【0006】従来、アレルゲンの除去法として、沈澱等
による分別、プロテアーゼ等による分解等の方法が報告
されているが、アレルゲン性の低減化はまだ不十分であ
り、苦味の発生や物性の変化等の問題が残っている。
[0006] Conventionally, as methods for removing allergens, methods such as separation by precipitation and decomposition by proteases have been reported, but reduction of allergenicity is still insufficient, and bitterness and physical properties are changed. The problem of remains.

【0007】一方、グルコシダーゼは、一般に、非発酵
性糖を含む水飴の製造や、糖蛋白質,糖脂質等から糖鎖
を遊離させ、その構成糖を解析する目的で使用されてお
り、糖蛋白質から糖鎖を遊離させた後に残った蛋白質に
ついての研究はなされていなかった。
[0007] On the other hand, glucosidase is generally used for the purpose of producing starch syrup containing non-fermentable sugar and for releasing sugar chains from glycoproteins, glycolipids, etc. and analyzing the constituent sugars. No studies have been done on the proteins that remained after releasing the sugar chains.

【発明が解決しようとする課題】[Problems to be Solved by the Invention]

【0008】従来の低アレルゲン化方法では、アレルゲ
ン性の低減化はまだ不十分であり、苦味の発生や物性の
変化等の問題があった。特に卵白の場合、プロテアーゼ
による分解では、卵白の特徴である熱凝固性が失われ、
その用途が限られてくるという問題があった。このた
め、卵白としての基本物性(熱凝固性,起泡性等)を保
持したまま低アレルゲン化したものが望まれている。本
発明の目的は、卵白としての基本物性(熱凝固性,起泡
性等)を保持したまま低アレルゲン化した卵白を提供す
ることである。
In the conventional methods for lowering allergens, reduction of allergenicity is still insufficient, and there are problems such as generation of bitterness and changes in physical properties. Especially in the case of egg white, decomposition by protease loses the thermocoagulability that is characteristic of egg white,
There was a problem that its use was limited. For this reason, it is desired that the egg white has a low allergen while maintaining the basic physical properties (eg, heat coagulation property and foaming property) as egg white. An object of the present invention is to provide an egg white having a reduced allergen while maintaining the basic physical properties (heat coagulation property, foaming property, etc.) of the egg white.

【0009】[0009]

【課題を解決するための手段】本発明者等は、鋭意研究
した結果、卵白をグルコシダーゼで処理することによっ
て、低アレルゲン化した卵白が提供できることを見出し
た。即ち、本発明は、グルコシダーゼを作用させること
により得られることを特徴とする低アレルゲン化卵白に
関する。
Means for Solving the Problems As a result of intensive studies, the present inventors have found that treating egg white with glucosidase can provide hypoallergenic egg white. That is, the present invention relates to a hypoallergenized egg white, which is obtained by allowing glucosidase to act.

【0010】本発明における、グルコシダーゼとは、糖
蛋白質,糖脂質等の糖鎖を切断する酵素であり、例え
ば、エンド−β−N−アセチルグルコサミニダーゼ,β
−N−アセチルヘキソサミニダーゼ,エンド−α−N−
アセチルガラクトサミニダーゼ,α−L−フコシダー
ゼ,α−N−アセチルガラクトサミニダーゼ,トランス
グルコシダーゼ,グリコペプチダーゼ,N−グリカナー
ゼ等があり、その起源は、アーモンド,ナタマメ等の植
物や、Flavobacterium sp.,Alcarigenes sp. ,Asperg
illus sp. 等の微生物等である。
The glucosidase in the present invention is an enzyme that cleaves sugar chains such as glycoproteins and glycolipids. For example, endo-β-N-acetylglucosaminidase, β
-N-acetylhexosaminidase, endo-α-N-
There are acetylgalactosaminidase, α-L-fucosidase, α-N-acetylgalactosaminidase, transglucosidase, glycopeptidase, N-glycanase and the like, and their origins are almonds, peanuts and other plants, and Flavobacterium sp., Alcarigenes. sp., Asperg
microorganisms such as illus sp.

【0011】本発明において、グルコシダーゼは、1種
類または2種類以上を組み合わせて使用され、その使用
方法としては、卵白溶液に直接添加する方法やグルコシ
ダーゼを固定化酵素とし、それを充填したカラムに卵白
溶液を通液する方法等があるが、後者の方が、酵素の失
活の処理が不要であるので望ましい。また、グルコシダ
ーゼを固定化酵素とする担体及び方法は公知のものでよ
い。
In the present invention, glucosidase is used alone or in combination of two or more kinds. As the method of using, glucosidase is directly added to the egg white solution or glucosidase is used as the immobilized enzyme, and the column filled with it is the egg white. Although there is a method of passing a solution, the latter method is preferable because the treatment for deactivating the enzyme is unnecessary. The carrier and method using glucosidase as the immobilized enzyme may be known.

【0012】本発明のグルコシダーゼによる処理温度
は、25〜70℃の温度範囲が望ましく、処理温度25
℃以下では酵素の活性が低くなり卵白の糖鎖の分解に長
時間必要になる問題がある。また処理温度70℃以上で
は酵素の失活が激しく、分解反応を制御することが困難
である。
The treatment temperature with the glucosidase of the present invention is preferably in the temperature range of 25 to 70 ° C., and the treatment temperature is 25
If the temperature is lower than ℃, the activity of the enzyme becomes low, and it takes a long time to decompose the sugar chain of egg white. At a treatment temperature of 70 ° C. or higher, the enzyme is inactivated so much that it is difficult to control the decomposition reaction.

【0013】本発明に用いる卵白は液卵白をそのまま、
又は、卵白粉末を水に2〜40重量%の範囲で溶解して
用いられるが、固形分の濃度が2重量%以下では酵素分
解反応は問題なく行われるが、低濃度のため得られる収
量が低くなる。また40重量%以上では溶液の粘度が上
昇し撹拌が困難となり、溶解が十分に行われにくくなる
などの問題がある。
The egg white used in the present invention is liquid egg white as it is,
Alternatively, the egg white powder is used by dissolving it in water in a range of 2 to 40% by weight. When the solid content is 2% by weight or less, the enzymatic decomposition reaction is carried out without problems, but the yield obtained is low. Get lower. On the other hand, if it is 40% by weight or more, there is a problem that the viscosity of the solution increases, stirring becomes difficult, and it becomes difficult to sufficiently dissolve it.

【0014】本発明の方法によって得られたグルコシダ
ーゼ処理卵白溶液は、そのまま液の形で、あるいは、減
圧濃縮などの方法で濃縮した液の形で、あるいはスプレ
ードライや凍結乾燥等の方法で粉末化した粉末状の形で
製品化することができる。
The glucosidase-treated egg white solution obtained by the method of the present invention is powdered as it is, in the form of a liquid, or in the form of a liquid concentrated by a method such as vacuum concentration, or by a method such as spray drying or freeze drying. It can be commercialized in the form of powder.

【0015】[0015]

【実施例】以下、実施例及び試験例により本発明を更に
詳しく説明するが、本発明はこれら実施例等に何ら限定
されるものではない。 実施例1 エンド−β−N−アセチルグルコサミニダーゼ〔住友精
化(株)製〕の固定化酵素30gを充填したカラム(2
0mmφ×500mm)に、卵白粉末50gを水500
mlに溶解した液を50℃に保ちながら、300ml/
時の速度で循環させながら5時間通液した後、カラムか
ら出てきた液を回収し、別容器に取った。回収したグル
コシダーゼ処理液を凍結乾燥し、グルコシダーゼ処理卵
白粉末を40g得た。
EXAMPLES The present invention will be described in more detail with reference to Examples and Test Examples, but the present invention is not limited to these Examples. Example 1 A column (2) packed with 30 g of an immobilized enzyme of endo-β-N-acetylglucosaminidase [Sumitomo Seika Co., Ltd.].
(0 mmφ x 500 mm), 50 g of egg white powder in 500 parts of water
While keeping the liquid dissolved in ml at 50 ° C, 300 ml /
After passing through the liquid for 5 hours while circulating the liquid at the same speed, the liquid coming out of the column was collected and put in another container. The collected glucosidase-treated liquid was freeze-dried to obtain 40 g of glucosidase-treated egg white powder.

【0016】試験例1.グルコシダーゼ処理卵白のアレ
ルゲン活性テスト。 実施例1で得たグルコシダーゼ処理卵白のアレルゲン活
性を、従来アレルゲンの同定に用いられている、RAS
Tキット〔ファルマシア社製〕を用いたRAST法で測
定し、原料の卵白粉末と比較した。試料(グルコシダー
ゼ処理卵白粉末又は原料卵白粉末)20mgを精製水10m
lに溶かした。この液にシアン化臭素で活性化した濾紙
ディスクを40〜50枚入れて3日間振盪し、試料の固定化
ディスクを作成した。余剰卵白は洗浄除去した。試料の
固定化ディスクに鶏卵アレルギー患者の血清を反応させ
た。血清の洗浄を行ない 125Iで標識した抗IgE抗体
を反応させ、洗浄後にガンマカウンターで計測した。鶏
卵アレルギーの患者10名の血清を使用して標準曲線を
作成し、本発明のグルコシダーゼ処理卵白と原料卵白と
を比較した。結果を図1に示す。
Test Example 1. Allergen activity test of glucosidase-treated egg white. The allergen activity of the glucosidase-treated egg white obtained in Example 1 is RAS, which has been conventionally used for identifying allergens.
It was measured by the RAST method using a T kit (manufactured by Pharmacia) and compared with the raw egg white powder. 20 mg of sample (glucosidase-treated egg white powder or raw egg white powder) in purified water 10 m
dissolved in 1. 40 to 50 filter paper discs activated with bromine cyanide were placed in this solution and shaken for 3 days to prepare a sample-immobilized disc. Excess egg white was washed off. The serum of an egg allergy patient was made to react with the fixed disk of the sample. The serum was washed, reacted with 125 I-labeled anti-IgE antibody, and after washing, measured with a gamma counter. A standard curve was prepared using the sera of 10 chicken egg allergy patients, and the glucosidase-treated egg white of the present invention was compared with the raw egg white. The results are shown in Fig. 1.

【0017】図1の結果より個人差は若干みられたもの
の、本発明のグルコシダーゼ処理卵白は原料卵白に比べ
てアレルゲン活性が低減していることが示された。
From the results shown in FIG. 1, it was shown that the glucosidase-treated egg white of the present invention had a reduced allergen activity as compared with the raw egg white, although there were some individual differences.

【0018】試験例2.卵白の基本物性についての試験 実施例1で得たグルコシダーゼ処理卵白の基本物性を確
認した。 (1)加熱凝固性 実施例1で得たグルコシダーゼ処理卵白粉末及び未処理
の卵白粉末各1gを各々10mlの水に溶解し、試験管
に取り、試験管の口にアルミホイルをかぶせ、沸騰水中
に試験管ごと5分間浸けたところ両者とも溶液は凝固
し、その凝固性に差異はみられなかった。
Test Example 2. Test on Basic Physical Properties of Egg White Basic properties of the glucosidase-treated egg white obtained in Example 1 were confirmed. (1) Heat Coagulation Property Glucosidase-treated egg white powder and untreated egg white powder (1 g) obtained in Example 1 were each dissolved in 10 ml of water, put into a test tube, covered with aluminum foil on the mouth of the test tube, and then in boiling water. When the test tube was immersed in the test tube for 5 minutes, both solutions coagulated and no difference was observed in their coagulability.

【0019】(2)気泡性 実施例1で得たグルコシダーゼ処理卵白粉末及び未処理
の卵白粉末各5gを各々50mlの水に溶解し、泡立て
器で攪拌したところ、よく泡立ち、強く攪拌を続ける
と、両者とも通常の液卵白と同様に細かく、硬い泡とな
り、その起泡性に差異はみられなかった。この結果よ
り、本発明のグルコシダーゼ処理卵白は、卵白としての
基本物性を失っていないことが示された。
(2) Foaming property Glucosidase-treated egg white powder and untreated egg white powder (5 g) obtained in Example 1 were each dissolved in 50 ml of water and stirred with a whisk. Both of them had fine and hard bubbles like ordinary liquid egg white, and there was no difference in their foaming properties. From these results, it was shown that the glucosidase-treated egg white of the present invention did not lose its basic physical properties as egg white.

【0020】[0020]

【発明の効果】本発明によれば、卵白をグルコシダーゼ
で処理することにより、低アレルゲン化卵白を得ること
ができる。本発明のグルコシダーゼ処理卵白は、卵白の
基本物性(熱凝固性,起泡性等)を保持したまま低アレ
ルゲン化されているので、卵白アレルギー患者であって
も摂食することのできる卵白として、通常の卵白と同様
に使用でき、卵白アレルギー患者用の食品の開発に役立
つものである。
According to the present invention, a hypoallergenic egg white can be obtained by treating egg white with glucosidase. The glucosidase-treated egg white of the present invention is a hypoallergen while maintaining the basic physical properties of the egg white (thermocoagulability, foaming property, etc.), so as an egg white that can be eaten even by an egg white allergy patient, It can be used like ordinary egg white and is useful for developing foods for patients with egg white allergy.

【0021】[0021]

【図面の簡単な説明】[Brief description of drawings]

【図1】実施例1のグルコシダーゼ処理卵白ディスクと
原料卵白ディスクとのRAST法による相関図である。
FIG. 1 is a correlation diagram of a glucosidase-treated egg white disc and a raw egg white disc of Example 1 by a RAST method.

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】 グルコシダーゼを作用させることにより
得られる低アレルゲン化卵白。
1. An allergen-reduced egg white obtained by allowing glucosidase to act.
JP5269679A 1993-09-30 1993-09-30 Albumen having decreased allergen content Pending JPH0799936A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP5269679A JPH0799936A (en) 1993-09-30 1993-09-30 Albumen having decreased allergen content

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5269679A JPH0799936A (en) 1993-09-30 1993-09-30 Albumen having decreased allergen content

Publications (1)

Publication Number Publication Date
JPH0799936A true JPH0799936A (en) 1995-04-18

Family

ID=17475687

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5269679A Pending JPH0799936A (en) 1993-09-30 1993-09-30 Albumen having decreased allergen content

Country Status (1)

Country Link
JP (1) JPH0799936A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006118098A (en) * 2004-10-22 2006-05-11 Q P Corp Material for paper coating composition, method for producing the same, and paper coating composition
WO2009107866A1 (en) * 2008-02-28 2009-09-03 味の素株式会社 Low-protein food and manufacturing method for same
KR101468004B1 (en) * 2012-06-22 2014-12-03 한국식품연구원 Method for preparing low antigenic egg white and hypoantigenic egg white produced thereby

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006118098A (en) * 2004-10-22 2006-05-11 Q P Corp Material for paper coating composition, method for producing the same, and paper coating composition
JP4637544B2 (en) * 2004-10-22 2011-02-23 キユーピー株式会社 Paper coating composition material, method for producing the same, and paper coating composition
WO2009107866A1 (en) * 2008-02-28 2009-09-03 味の素株式会社 Low-protein food and manufacturing method for same
KR101468004B1 (en) * 2012-06-22 2014-12-03 한국식품연구원 Method for preparing low antigenic egg white and hypoantigenic egg white produced thereby

Similar Documents

Publication Publication Date Title
Hawk Practical physiological chemistry
WO2016173222A1 (en) Hypoallergenic, odor-reduced fish protein oligopeptide, industrialized preparation method for same, and applications thereof
Morris et al. Trypsinogen deficiency disease
US5096894A (en) Rice dextrin oral rehydration solution
JP3557711B2 (en) Foods and manufacturing methods effective for improving lipid metabolism
CN111096462B (en) Green biological enzymolysis purified bird's nest polypeptide and debitterizing method thereof
JPH0799936A (en) Albumen having decreased allergen content
CN109806383A (en) A kind of sea eel peptide promotes the application in immune food, drug or health care product in preparation
Christensen et al. Determination of the plasma glycine after gelatin feeding as a diagnostic procedure for pancreatic fibrosis
JP4684440B2 (en) Lipid peroxide elevation-suppressing composition containing mannooligosaccharide
Himwich et al. The metabolic effects of potassium, temperature, methylene blue and paraphenylenediamine on infant and adult brain
Yehuda et al. Long lasting effects of infancy iron deficiency—preliminary results
Rasmussen et al. “Covert toxocariasis” in a child treated with low‐dose diethylcarbamazine
CN105815788A (en) Healthy substitute sugar and method for preparing healthy substitute sugar through liquid state fermentation technology
JPH07115920A (en) Production of allergen-reduced rice
CN108175019B (en) Red date enzyme beverage and processing technology thereof
JP2900070B2 (en) Potassium supplement composition for food and method for producing the same
Pølling et al. A method for the estimation of phenylpyruvic acid in urine with some examples of its use in dietary treatment of phenylpyruvic oligophrenia
JPH11269078A (en) Calcium absorption promoter and calcium-replenishing food and drink
CN110122572B (en) Chromium-rich functional milk powder based on chromium-rich mushroom mycelium for protecting eyesight
JP2007063236A (en) Composition for improving quality of sleep
JPH11225686A (en) Casein hydrolysate and its production
CN110075128A (en) A kind of pharmaceutical compositions for being used to enhance immune function comprising enzyme treated bee milk powder as effective component
JP2001048794A (en) Health food and medicinal composition which contain mixture of powder originated from leaf of mulberry and powder originated from oyster and is used for treating niddm
Lietze Laboratory Research in Food Allergy I. Food Allergens